et al., EP Europace, doi:10.1093/europace/euaa216
(Peer Reviewed) (not included in the study count)
Arrhythmic safety of hydroxych loroquine in COVID-19 patients from different clinical settings
Safety study of 649 patients finding that HC
Q administration is safe for short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths.
Arrhythmic safety data from a large cohort of patients treated with HC
Q alone or in combination with other QT-prolonging drugs.
Please send us corrections, updates, or comments.